Trial Profile
Phase III Study of Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary) ; Bevacizumab; Docetaxel
- Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 13 Feb 2018 Status changed from recruiting to completed.
- 06 Jun 2017 Results (n=147) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 11 Nov 2016 New trial record